Epilepsy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Part 1 – Main study:
- People aged 18 or older who have been diagnosed with epilepsy, have completed a surgical evaluation at Cleveland Clinic, and have been recommended for brain surgery or a neurostimulation device implant.
Part 2a – Patient survey:
- People aged 18 or older who have been diagnosed with epilepsy, have been evaluated for epilepsy surgery, and have enough English proficiency to complete a survey.
Part 2a – Healthcare provider survey:
- Healthcare professionals based in the US who are involved in the care or treatment of people with epilepsy.
Part 2b – Cleveland Clinic patient focus groups:
- People aged 18 or older who have been diagnosed with epilepsy, have previously completed an epilepsy workup at Cleveland Clinic, have basic conversational English skills (assessed by phone), and have no signs of dementia or intellectual disability that would affect their ability to take part.
Part 2b – Cleveland Clinic provider focus groups:
- Clinicians who are members of the Cleveland Clinic Epilepsy Center and care for patients with epilepsy.
Part 2b – Community patient focus groups:
- People aged 18 or older who have been diagnosed with epilepsy, have previously completed an epilepsy workup (at any location), and have basic conversational English skills (assessed by phone), with no signs of dementia or intellectual disability that would affect participation.
Part 2b – Community provider focus groups:
- Clinicians who provide care to people with epilepsy outside of Cleveland Clinic.
Part 3:
- People aged 18 or older who are fluent in English and are currently being evaluated for epilepsy surgery at the Cleveland Clinic Epilepsy Monitoring Unit.
Who may not be able to join:
Part 1:
- People who have previously had epilepsy surgery or already have a neurostimulation device implanted.
Part 2a – Patient survey:
- People who are not able to read English fluently, or who have signs of dementia or intellectual disability that would affect their understanding of the survey questions.
Part 2a – Healthcare provider survey:
- Healthcare providers who are not able to read English fluently.
Part 2b – Cleveland Clinic patient focus groups:
- People who are not fluent in English, have signs of dementia or intellectual disability that would affect their ability to participate, or have previously had epilepsy surgery.
Part 2b – Cleveland Clinic provider focus groups:
- Clinicians who were involved in designing this study.
Part 2b – Community patient focus groups:
- People who are not fluent in English, have signs of dementia or intellectual disability that would affect their ability to participate, or have previously had epilepsy surgery.
Part 3:
- People who are not fluent in English, or who have signs of dementia or intellectual disability that would affect their understanding of the study intervention.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Anny Reyes, PhD, The Cleveland Clinic
Phone: 216-390-4266
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part 2a: Identify primary barriers to accessing and undergoing epilepsy surgery; Part 2b: Further identify barriers associated with lack of access and utilization of epilepsy surgery; Part 3: Determine acceptability of PEERS Program; Part 3: Determine satisfaction of PEERS Program; Part 3: Determine effectiveness of PEERS Program
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.